drugset
drugset / Trial / NCT00129844

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

NCT00129844 ↗

Phase 2 Completed 108 enrolled Pharmacyclics LLC.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effect of MGd in non-small-cell lung cancer (NSCLC) when given alone, and to evaluate the difference between two dosing regimens.

Timeline

Start
2005-09
Primary completion
2007-06
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject motexafin gadolinium Diagnostic / imaging agent 10 mg/kg —
Subject motexafin gadolinium Diagnostic / imaging agent 15 mg/kg —

Indications

adenocarcinoma non-small cell lung carcinoma